Skip to main content

Table 2 Summary of AQLQ completers at each time point during the study

From: Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life

Timepoint

SAL/FP

FOR/BUD

Total ITT population

344

344

AQLQ completers

  

At least once during study

280

288

Baseline

278

286

Total Week 5–52 population

295

286

AQLQ completers

  

Week 28

173 (59)†

166 (58)†

Week 52

158 (54)†

155 (54)†

  1. AQLQ = Asthma Quality of Life Questionnaire; FOR/BUD = formoterol/budesonide combination; ITT = intent to treat; SAL/FP = salmeterol/fluticasone propionate combination.
  2. † Percentage of Week 5–52 population
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us